{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:29:52Z","timestamp":1788564592838,"version":"build-2803163510"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2012,11,2]],"date-time":"2012-11-02T00:00:00Z","timestamp":1351814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0048706","type":"journal-article","created":{"date-parts":[[2012,11,2]],"date-time":"2012-11-02T17:03:19Z","timestamp":1351875799000},"page":"e48706","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Protection of Rabbits and Immunodeficient Mice against Lethal Poxvirus Infections by Human Monoclonal Antibodies"],"prefix":"10.1371","volume":"7","author":[{"given":"Lindsay","family":"Crickard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahar","family":"Babas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Silvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Koriazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,11,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"281","author":"DA Henderson","year":"1999","journal-title":"Jama"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","article-title":"Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy","volume":"10","author":"R Wittek","year":"2006","journal-title":"Int J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/375824","article-title":"Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions","volume":"37","author":"VA Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref4","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I (2001) Smallpox and its Eradication. 4."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1086\/498115","article-title":"Clinical characteristics of human monkeypox, and risk factors for severe disease","volume":"41","author":"GD Huhn","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nm1273","article-title":"Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox","volume":"11","author":"E Hammarlund","year":"2005","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/CVI.00148-07","article-title":"Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection","volume":"14","author":"KL Karem","year":"2007","journal-title":"Clinical and Vaccine Immunology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/505880","article-title":"Clinical manifestations of human monkeypox influenced by route of infection","volume":"194","author":"MG Reynolds","year":"2006","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2007.10.063","article-title":"Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge","volume":"26","author":"KA Marriott","year":"2008","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"RN Greenberg","year":"2008","journal-title":"Expert opinion on investigational drugs"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Fulginiti VA (2003) Risks of smallpox vaccination. Jama 290: 1452; author reply 1452.","DOI":"10.1001\/jama.290.11.1452-a"},{"key":"ref12","unstructured":"Neff JM, Lane JM, Fulginiti VA (2003) Smallpox and smallpox vaccination. N Engl J Med 348: 1920\u20131925; author reply 1920\u20131925."},{"key":"ref13","first-page":"1","article-title":"Smallpox Vaccination and Adverse Reactions","volume":"52","author":"J Cono","year":"2003","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"VA Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, <etal>et al<\/etal>.. (2009) Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med.","DOI":"10.1084\/jem.20082835"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/422999","article-title":"Clinical efficacy of intramuscular vaccinia immune globulin: a literature review","volume":"39","author":"RJ Hopkins","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.26.2.176","article-title":"Studies on smallpox and complications of smallpox vaccination","volume":"25","author":"CH Kempe","year":"1960","journal-title":"Pediatrics"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinial gamma globulin","volume":"18","author":"CH Kempe","year":"1956","journal-title":"Pediatrics"},{"key":"ref19","first-page":"325","article-title":"The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox","volume":"27","author":"SS Marennikova","year":"1962","journal-title":"Bull World Health Organ"},{"key":"ref20","first-page":"59","article-title":"Immunotherapie de la Variole","volume":"1","author":"G Couzi","year":"1941","journal-title":"Bulletin de l\u2019Institut d\u2019hygiene du Maroc"},{"key":"ref21","unstructured":"Corporation BH (1995) Vaccinia Immune Globulin (Human) package insert. In: Corporation BH, editor."},{"key":"ref22","unstructured":"Dynport Vaccine Company (2005) Vaccinia Immune Globulin Intravenous (Human) (VIGIV) package insert. In: CBER F, editor."},{"key":"ref23","unstructured":"Cangene Corporation (2005) Vaccinia Immune Globulin Intravenous (Human) (VIGIV) package insert. In: CBER F, editor."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1128\/AAC.49.7.2634-2641.2005","article-title":"Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection","volume":"49","author":"JD Shearer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.0042-9007.2004.00397.x","article-title":"Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia","volume":"86","author":"JC Goldsmith","year":"2004","journal-title":"Vox Sang"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Y Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","article-title":"Immunity and immunological memory following smallpox vaccination","volume":"211","author":"IJ Amanna","year":"2006","journal-title":"Immunol Rev"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: targets of protective immunity","volume":"239","author":"B Moss","year":"2011","journal-title":"Immunological reviews"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"E Bell","year":"2004","journal-title":"Virology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1086\/520936","article-title":"Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccine-Induced Immunity","volume":"196","author":"Y He","year":"2007","journal-title":"J Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox","volume":"7","author":"DH Davies","year":"2007","journal-title":"Proteomics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"DH Davies","year":"2005","journal-title":"J Virol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine","volume":"82","author":"MR Benhnia","year":"2008","journal-title":"J Virol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"S Lustig","year":"2005","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1086\/520936","article-title":"Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine\u2013induced immunity","volume":"196","author":"Y He","year":"2007","journal-title":"The Journal of infectious diseases"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3851\/IMP1573","article-title":"Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model","volume":"15","author":"MM McCausland","year":"2010","journal-title":"Antiviral therapy"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1128\/JVI.01593-09","article-title":"Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5","volume":"83","author":"MR Benhnia","year":"2009","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3851\/IMP1717","article-title":"Protective murine and human monoclonal antibodies against eczema vaccinatum","volume":"16","author":"Y Tomimori","year":"2011","journal-title":"Antiviral therapy"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement","volume":"83","author":"MR-E-I Benhnia","year":"2009","journal-title":"Journal of Virology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"107","author":"DW Grosenbach","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","article-title":"Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus","volume":"103","author":"Z Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e1002475","DOI":"10.1371\/journal.ppat.1002475","article-title":"Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver","volume":"8","author":"RH Xu","year":"2012","journal-title":"PLoS pathogens"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"J Huggins","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"S Parker","year":"2008","journal-title":"Antiviral research"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0048706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T15:50:56Z","timestamp":1643557856000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0048706"}},"subtitle":[],"editor":[{"given":"Zhiwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,2]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0048706","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,2]]}}}